Literature DB >> 31669619

The changing landscape of clinical trials for mitochondrial diseases: 2011 to present.

Delia Khayat1, Tracie L Kurtz1, Peter W Stacpoole2.   

Abstract

We reviewed the status of interventional clinical trials for primary mitochondrial diseases. Using national and international search engines, we found 48 randomized controlled trials (RCTs) registered as of May 15, 2019. Consilience between lay and professional mitochondrial disease communities to engage in RCTs has increased, as has progress in developing new disease and treatment biomarkers and potential therapies. The continued advancement of general knowledge of mitochondrial biology has fostered appreciation for the fundamental role mitochondria play in the etiopathology of other rare and common illnesses, emphasizing the therapeutic potential of mitochondrially-targeted small molecules for an increasing spectrum of human diseases.
Copyright © 2019 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Entities:  

Year:  2019        PMID: 31669619      PMCID: PMC6934893          DOI: 10.1016/j.mito.2019.10.010

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  23 in total

Review 1.  Two decades of orphan product development.

Authors:  Marlene E Haffner; Janet Whitley; Marie Moses
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

Review 2.  Socio-economic burden of rare diseases: A systematic review of cost of illness evidence.

Authors:  Aris Angelis; David Tordrup; Panos Kanavos
Journal:  Health Policy       Date:  2014-12-30       Impact factor: 2.980

3.  Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism.

Authors:  Kathryn M Camp; Michele A Lloyd-Puryear; Lynne Yao; Stephen C Groft; Melissa A Parisi; Andrew Mulberg; Rashmi Gopal-Srivastava; Stephen Cederbaum; Gregory M Enns; Abby G Ershow; Dianne M Frazier; John Gohagan; Cary Harding; R Rodney Howell; Karen Regan; Peter W Stacpoole; Charles Venditti; Jerry Vockley; Michael Watson; Paul M Coates
Journal:  Mol Genet Metab       Date:  2013-05-23       Impact factor: 4.797

4.  Development of a novel observer reported outcome tool as the primary efficacy outcome measure for a rare disease randomized controlled trial.

Authors:  Peter W Stacpoole; Jonathan Shuster; John L P Seamus Thompson; Robert A Prather; Lee Ann Lawson; Baiming Zou; Richard Buchsbaum; Sara Jo Nixon
Journal:  Mitochondrion       Date:  2017-11-10       Impact factor: 4.160

5.  Initial experience in the treatment of inherited mitochondrial disease with EPI-743.

Authors:  Gregory M Enns; Stephen L Kinsman; Susan L Perlman; Kenneth M Spicer; Jose E Abdenur; Bruce H Cohen; Akiko Amagata; Adam Barnes; Viktoria Kheifets; William D Shrader; Martin Thoolen; Francis Blankenberg; Guy Miller
Journal:  Mol Genet Metab       Date:  2011-10-21       Impact factor: 4.797

6.  A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.

Authors:  Quincy Siu-Chung Chu; Randeep Sangha; Jennifer Spratlin; Larissa J Vos; John R Mackey; Alexander J B McEwan; Peter Venner; Evangelos D Michelakis
Journal:  Invest New Drugs       Date:  2015-03-13       Impact factor: 3.850

7.  The measurement of performance in childhood cancer patients.

Authors:  S B Lansky; M A List; L L Lansky; C Ritter-Sterr; D R Miller
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

8.  Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate.

Authors:  R M Bersin; C Wolfe; M Kwasman; D Lau; C Klinski; K Tanaka; P Khorrami; G N Henderson; T de Marco; K Chatterjee
Journal:  J Am Coll Cardiol       Date:  1994-06       Impact factor: 24.094

9.  Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia.

Authors:  P W Stacpoole; G W Moore; D M Kornhauser
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

Review 10.  Unintended effects of orphan product designation for rare neurological diseases.

Authors:  Sinéad M Murphy; Araya Puwanant; Robert C Griggs
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

View more
  3 in total

Review 1.  Multifaceted Roles of Mitochondrial Components and Metabolites in Metabolic Diseases and Cancer.

Authors:  Jean Nakhle; Anne-Marie Rodriguez; Marie-Luce Vignais
Journal:  Int J Mol Sci       Date:  2020-06-20       Impact factor: 5.923

2.  Neuronal cell-based high-throughput screen for enhancers of mitochondrial function reveals luteolin as a modulator of mitochondria-endoplasmic reticulum coupling.

Authors:  Luana Naia; Catarina M Pinho; Giacomo Dentoni; Jianping Liu; Nuno Santos Leal; Duarte M S Ferreira; Bernadette Schreiner; Riccardo Filadi; Lígia Fão; Niamh M C Connolly; Pontus Forsell; Gunnar Nordvall; Makoto Shimozawa; Elisa Greotti; Emy Basso; Pierre Theurey; Anna Gioran; Alvin Joselin; Marie Arsenian-Henriksson; Per Nilsson; A Cristina Rego; Jorge L Ruas; David Park; Daniele Bano; Paola Pizzo; Jochen H M Prehn; Maria Ankarcrona
Journal:  BMC Biol       Date:  2021-03-24       Impact factor: 7.431

Review 3.  Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention.

Authors:  Melissa A E van de Wal; Merel J W Adjobo-Hermans; Jaap Keijer; Tom J J Schirris; Judith R Homberg; Mariusz R Wieckowski; Sander Grefte; Evert M van Schothorst; Clara van Karnebeek; Albert Quintana; Werner J H Koopman
Journal:  Brain       Date:  2022-03-29       Impact factor: 13.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.